Hello, I have had a chest x-ray twice for muscle pain. The first time it said I had a calcified aorta, but the second time it didn't say anything about that. What is the cause? Are X-rays reliable for that diagnosis?

Excelent webinars

Forward CarePod is good AI from what I have read,and I myself have congestive heart failure and getting my cardiologist to agree with this and CIMT test or ccta along With AI CarePod he is looking at the numbers and medications which I and many others don't agree with. The technology is here a day this Is a 200yr old research hospital plus university so being in a rural area its not convenient plus I caregive also.

Summary of the long discussion - Ultra-thin strut stents, defined by a thickness of ≤70 microns, are emerging as a significant advancement in interventional cardiology. Initial studies, such as those by Castrati in 2003, demonstrated that thinner struts reduce restenosis and target lesion revascularization (TLR) rates compared to thicker struts. Recent meta-analyses confirm that thinner struts lower myocardial infarction rates and stent thrombosis, improving overall outcomes. Their reduced crossing profile enhances deliverability, especially in complex anatomies, without compromising radial strength or visibility due to advancements in cobalt-chromium materials. These platforms also reduce trauma, improve laminar blood flow, and decrease inflammatory responses, contributing to better healing and reduced enzyme leakage. Studies like the TALENT trial show that ultra-thin strut stents are non-inferior to standard thin-strut DES and offer significant reductions in ischemia-driven TLR. Faster endothelialization observed with these stents supports shorter dual antiplatelet therapy (DAPT) durations, making them ideal for high-bleeding risk patients or those requiring urgent surgery. They also perform well in small vessel disease (≤2.5 mm) and in-stent restenosis by minimizing metal burden. Importantly, ultra-thin struts maintain adequate radial strength (>800 mmHg) to withstand clinical pressures. While the concept holds promise, questions remain regarding the lower limit of strut thickness without compromising safety or efficacy. Future studies, particularly in populations with diabetes and multi-vessel disease, will clarify their role in addressing more complex cases. Preliminary data suggest ultra-thin strut stents may reduce myocardial infarction rates by lowering enzyme leaks, improve long-term patency, and potentially shift guidelines favoring surgical revascularization in diabetes. Clinical trials also point to improved outcomes in elderly and high-risk populations, where safety and efficacy are paramount. With broader adoption, these stents may redefine interventional cardiology practices by addressing the unmet needs of increasingly complex cases. In conclusion, ultra-thin strut stents are a promising innovation, enhancing safety, efficacy, and deliverability while reducing restenosis and inflammatory responses. As data accumulate, these stents may become a preferred option for managing complex coronary artery disease. Their role in the future of interventional cardiology warrants continued exploration through rigorous clinical trials.

Para mí es importante pero no ablamos inglés

Desirlo en español

Thanks sir for this program, it help us I am a technician

Meilleur équipe Faurie et Monségu les best . Grenoble la Mut .

Of course we enjoyed it. Many thanks to you all for ypur great effort on this important issue.

No

Indian busted

Interesting

Dear very good presentation. What's DAPT for routine patient on DEB patients?? Any change for long DEB like 10- 20mm or two or more DEB in same patient then what DAPT for that according to guidelines

very informative webinar..

Very good thank you

THE CX IS NOT SO IMPORTANT. IT IS A SIMPLE BIFURCATION LESION. LAD AND INTERMEDIUM BRANCH

Very amazing thanks professeurs❤

If it is causing angina and has a size more than 2 mm then do ptca

Great presentation If we have stent at the dot like xience expedition dr Adrian is talking about these stents will pacing at side branch osmium when he mentions that stent balloon dot overlaps the main wire most likely then ostium is nailed

Excellent discussion, great teachers

The Ross procedure in below 65 yo is recommended for aortic valve replacement with autograf of pulmonary valve to the aortic valve and allograf to pulmonary valve with ideal life expectancy ROSSkzbin.info/www/bejne/joureKSHdtSqn6ssi=DjSCDG2CxUuqTUr9

This discussion is full of what is called specialty bias. These are 2 structural interventional cardiologists, wanting to do procedures for reimbursements. Specially the casualness of blowing off atrial fibrillation as a cause of cardioembolic stroke.......it is bordering on malpractice. More and more data has shown that atrial fibrillation (specially paroxysmal atrial fibrillation) is the cause of 20% of all stroke and a large number of cryptogenic strokes when monitored with implantable loop recorders (16-24%) will catch PAF. Besides no one discusses that 10% or more of PFO closures when monitored for 1 year were found to be in atrial fibrillation.......requiring anticoagulation for secondary stroke prevention........thus defeating PFO closure in the first place. Just yesterday I saw a patient in my practice with an embolic stroke who "had previously had a PFO closure". He was on aspirin and clopidogrel. His TEE showed a thrombus sitting in the left atrium on top of the closure device. With the WATCHMAN device, we already know that 24% of them can have a thrombus sitting on the device within 1 year of getting off anticoagulation. Listening to such a biased discussion with 2 interventionalists who appear to be poorly familiar with evidence, have financial incentives to do more procedures is near criminal. Where are the academic stroke neurologists here who have participated in some (not all) of these industry sponsored trials?

Thank you for that you made me learned a new thing today.

The conversation is not understood

kzbin.info/www/bejne/eZLUc3mwqLSbeKssi=4YYWRERoJ3ocQj4Z

Vary informative session ,Thank you

🎯 Key points for quick navigation: 00:20 *Javier Escaned lidera el estudio DCR4 para reducir el uso de contraste en intervenciones coronarias percutáneas (PCI).* 00:46 *El estudio se enfoca en pacientes sensibles al contraste yodado, especialmente aquellos con enfermedad renal crónica.* 01:25 *La tecnología probada es el Dynamic Coronary Road Mapping, que busca reducir la administración de contraste durante el PCI.* 02:06 *Se realizó un ensayo clínico aleatorizado con unos 350 pacientes en EE.UU., Europa e Israel, comparando el uso convencional con el Dynamic Coronary Road Mapping.* 02:35 *El grupo que utilizó el mapeo dinámico mostró una reducción significativa en el uso de contraste.* 03:46 *La tecnología es parte del sistema de rayos X y no requiere elementos adicionales para el paciente, mejorando la navegación constante sin pruebas adicionales de contraste.* 04:39 *Se observó una reducción de 25 ml de contraste en procedimientos complejos, especialmente beneficioso para lesiones vasculares complicadas.* 05:44 *A medida que aumenta la complejidad del PCI, la tecnología demuestra mayor beneficio en la reducción de contraste.* 06:11 *Aunque el estudio no se centró en pacientes con enfermedad renal crónica grave, el uso de contraste se redujo significativamente en general.* 07:08 *La curva de aprendizaje es corta y la tecnología podría ser utilizada como técnica predeterminada para guiar procedimientos de PCI, evitando pruebas adicionales de contraste.* Made with HARPA AI

🎯 Key points for quick navigation: 00:00 *Introduction to EuroPCR 2023 with Justin Davis and Patricia and discussion of the Fine Flair 5-year follow-up and Reveal trial.* 00:47 *Define Flair study tested IFR against FFR showing IFR's non-inferiority in a large patient group, with a significant finding in favor of FFR regarding mortality.* 01:55 *Comparison to Sweetheart study shows similar findings except for mortality, raising interest in geographic disparity considerations in clinical trials.* 02:50 *Discussion about geographic disparities affecting trial results with differing baseline characteristics and treatment methods across different countries.* 05:18 *Key insights on mortality causes and specific characteristics of patients who died during the IFR and FFR trials.* 06:40 *Mortality signals not directly related to increased myocardial infarction or revascularization, requiring further investigation.* 07:32 *The Reveal trial validates a new angio FFR software, noting differences among various software solutions with a focus on accuracy and speed.* 10:42 *Angio FFR could serve as a transitional technology, with increased use of CT and FFR scans in Europe indicating a move toward non-invasive diagnostics.* 12:03 *Future cath lab procedures may integrate both CT and angio-based tools for comprehensive, rapid diagnosis and treatment planning, augmenting traditional methods.* Made with HARPA AI

😢 I think that the study should be repeated but on more heterogeneous patients.

My favorite two doctors discussing my Favorite subject. DCBs rock. Keep it up!

They cant find Afib on me with 5 days of hospital monitoring plus on mobile ecg for 2 weeks ( this factor was the last criteria to be ruled out) and during my follow up appointment, sent me off to monitor myself with an Apple watch for the next 5 months! This is ridiculous!

I always enjoy the webinars with Dr Stankovich, they are really scientific and educational based on the latest studies

Great presentation and looking forward to use the new Valve FX+

Thanks for the great videos, they are really informative and beneficial. There is something that I noted here: at 10:06min the POT balloon was on the SB wire (which looked re-wired) and not in the MB wire. Can we do POT using a rewired SB wire?

As a MINOCa patient who cannot tolerate any of the medications available I found this very helpful and informative. Thank you.

Thanks

Thank you so so much for answering many questions that were in my head!! I have my surgery in about a week and feel better after listening to you!

You used the same clip for FFR its making me confuse

Georg Nickenig is involved in the scandal sourrounding Prof Maisano from Zurich concerning Cardioband as well as Cardiovalve. Studies have been falsified and a lot of atient were unecessarily harmed. Take that into conseration while wathcing this video

This clip hasn't aged well. Check the scandal around Maisano his death tall and the manipulation arround Cardioband.

Amazing

Nothing of value 😏

❤Amen

I'd get TAVR for sure. There's a recent 10 year study out recently.

Fucking england protests east india terrorist company distroyed nepal nepali culture nepal kingdom

Thanks!

I have had 4 new valves fitted long process

😊 😊L😊 😊 😊😊 😊😊 O😊 😊 😊 😊 😊

A quick one if i may, not all antianginals had no prognostic effects, BB first-line anti anginal therapy have some prognostic effects?